ClinicalTrials.gg
CompletedNCT05906836Updated Sep 16, 2025Results posted

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

A Phase 1 interventional study of Rosuvastatin and Selpercatinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to determine the effect of selpercatinib on the levels of rosuvastatin in the blood stream in healthy participants. This study also evaluated the safety and tolerability of rosuvastatin when administered in combination with selpercatinib in healthy participants. This study will last up to approximately 26 days excluding screening period.

02

Conditions studied

  • Healthy

Keywords

  • Drug Drug Interaction Trial
  • Selpercatinib (Retevmo®)
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation
  • Participant must be Caucasian
  • (BMI) within the range of 19.0 to 32.0 kilograms per meter squared (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to selpercatinib-related compounds or any components of the formulation of selpercatinib, or or rosuvastatin
    • Have a significant previous or current history or presence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the product
  • Have used or are intending to use over-the-counter or prescription medication, including dietary supplements and herbal medications, within 14 days prior to dosing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Rosuvastatin + Selpercatinib

    Participants received 20 milligram (mg) of rosuvastatin administered orally on Day 1, followed by 20 mg of rosuvastatin coadministered orally with 160 mg of selpercatinib on Day 5.

    Drug: Rosuvastatin · Drug: Selpercatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin

    PK: Cmax of Rosuvastatin was reported.

    Time frame: Day 1 and Day 5: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours (h) post dose

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Rosuvastatin

    PK: AUC(0-∞) of Rosuvastatin was reported.

    Time frame: Day 1 and Day 5: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h post dose

07

Results

Posted Sep 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneRosuvastatin + Selpercatinib
Started28
Completed26
Not completed2
Withdrew: Unwilling to make travel arrangements1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin

PK: Cmax of Rosuvastatin was reported.

Time frame:
Day 1 and Day 5: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours (h) post dose
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin
nanogram per millilitre (ng/mL)RosuvastatinRosuvastatin + Selpercatinib
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin8.92 ± 5915.2 ± 38
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Rosuvastatin

PK: AUC(0-∞) of Rosuvastatin was reported.

Time frame:
Day 1 and Day 5: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 h post dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Rosuvastatin
nanogram*hour per milliliter (ng*hr/mL)RosuvastatinRosuvastatin + Selpercatinib
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Rosuvastatin81.9 ± 70151 ± 44

Adverse events

Collected over Baseline Up to Day 15. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin0/28 (0%)0/28 (0%)0/28 (0%)
Rosuvastatin + Selpercatinib0/28 (0%)0/28 (0%)0/28 (0%)

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Rosuvastatin + Selpercatinib
Mean41.5 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin + Selpercatinib
Female10
Male18
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rosuvastatin + Selpercatinib
Hispanic or Latino10
Not Hispanic or Latino18
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rosuvastatin + Selpercatinib
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White27
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Rosuvastatin + Selpercatinib
United States28
08

Study locations

1 site
  • Labcorp Clinical Research LP
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Oct 2023, 3 months.

Results were first posted in Sep 2025, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2023
First posted
Jun 18, 2023
StartActual
Jul 27, 2023
Primary completionActual
Oct 31, 2023
CompletionActual
Oct 31, 2023
Results first posted
Sep 16, 2025
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05906836
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jul 27, 2023
Primary completion
Oct 31, 2023
Completion
Oct 31, 2023
Results posted
Sep 16, 2025
Last update
Sep 16, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Selpercatinib

Start the discussion